Cognition Therapeutics
Clinical trials sponsored by Cognition Therapeutics, explained in plain language.
-
Experimental drug zervimesine made available to patients with lewy body dementia
Disease control NO_LONGER_AVAILABLEThis expanded access program offers the experimental drug zervimesine (CT1812) to people aged 50 to 86 with mild-to-moderate dementia with Lewy bodies. Participants take one 100 mg pill daily for up to a year. The goal is to provide access to the drug and collect long-term safety…
Sponsor: Cognition Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
Could a Synapse-Targeting drug slow Alzheimer's?
Disease control OngoingThis Phase 2 trial tests an experimental drug called CT1812 in 540 people with early Alzheimer's disease. Participants receive either the drug or a placebo for 18 months. The goal is to see if CT1812 can slow declines in memory, thinking, and daily function. The study is active b…
Phase: PHASE2 • Sponsor: Cognition Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC